Evidence map›Paper›PMID 22510383›Full record

ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2012

Secondary treatment of acute graft-versus-host disease: a critical review.

Paul J Martin, Yoshihiro Inamoto, Mary E D Flowers, Paul A Carpenter

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07708987 (A Phase II Clinical Trial of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease), which is not on this map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07708987 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase II Clinical Trial of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease

TypeinterventionalSponsorTata Memorial CentreRan2023 to 2028Enrolled34ConditionsHematological Malignancy, GVHD - Graft-Versus-Host Disease, Steriod RefractoryArmsStandardized Withaferin A (SWA)
3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Paul J MartinDivision of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA. pmartin@fhcrc.org
Yoshihiro Inamoto
Mary E D Flowers
Paul A Carpenter

Funding

Mycophenylate Mofetil for Treatment of Chronic GVHDR01CA098906 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MARTIN, PAUL J · 2003 to 2008
$2.3M
NCI NIH HHS CA98906NCI NIH HHS R01 CA098906
6 · The paper itself

Abstract

Management of steroid-resistant or steroid-refractory acute graft-versus-host disease (aGVHD) poses one of the most vexing and difficult problems faced by transplantation physicians. In the current study, we used 10 criteria to evaluate 67 reports describing secondary treatment of patients with aGVHD. The goal of this exercise was not only to provide a critical summary of the literature but also to offer suggestions that could improve future studies. Areas especially in need of improvement include the use of a consistent treatment regimen, the assessment of response at a consistent prespecified time point, consideration of concomitant treatment in assessing response, documentation that selection bias was minimized, and the use of methods that test a formal statistical hypothesis based on a contemporaneous or historical benchmark. Our results suggest that previous published reports collectively offer little guidance in discerning the most effective treatments for patients with steroid-resistant or steroid-refractory aGVHD. Adherence to the proposed criteria in future reports would enable meaningful comparisons across studies and thereby accelerate progress in evaluating new treatments for patients with aGVHD.

Indexed as

Hematopoietic Stem Cell TransplantationAcute DiseaseAntineoplastic AgentsBiomarkers, PharmacologicalDatabases, BibliographicDisease ManagementEpidemiologic StudiesGraft vs Host DiseaseHumansPatient SelectionResearch DesignSelection BiasSteroidsTransplantation, HomologousTreatment OutcomeAntineoplastic AgentsBiomarkers, PharmacologicalSteroids

Identifiers

PMID22510383
PMCPMC3386268

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.